Type 1 diabetes is caused by the immune system mistakenly destroying the insulin-producing beta cells in the pancreas. The process is autoimmune: the body’s own T cells identify beta cells as foreign and progressively wipe them out, eventually leaving a person unable to produce enough insulin to regulate blood sugar. But autoimmunity doesn’t ignite on its own. It requires a genetic predisposition, and something in the environment appears to light the fuse. Pinpointing exactly what pulls that trigger has kept researchers busy for decades, and the emerging picture involves viruses, gut bacteria, diet, and factors that may begin before birth.
How the Immune System Destroys Beta Cells
The core event in type 1 diabetes is a targeted attack by T cells on the beta cells of the pancreatic islets.1PubMed Central. T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes Several immune players work together. Dendritic cells and macrophages in the pancreas pick up proteins shed by beta cells and present fragments of those proteins to helper T cells. Once activated, these helper T cells release chemical signals that ramp up the immune response, calling in cytotoxic T cells that directly kill beta cells.2PubMed. Autoimmune destruction of pancreatic beta cells B cells also get involved, producing autoantibodies against beta cell proteins. Those autoantibodies serve as early warning markers in research, but the actual killing is done by T cells.
One reason the attack sustains itself has to do with regulatory T cells, or Tregs. These are the immune system’s internal brakes, normally tasked with shutting down immune responses that target the body’s own tissues. In people who develop type 1 diabetes, Tregs don’t seem to work properly within the pancreatic environment. Research suggests the problem isn’t that people have too few Tregs overall but that these cells are functionally impaired right where they’re needed most.3Frontiers in Endocrinology. Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes That functional failure allows the autoimmune attack to continue unchecked, grinding down beta cell mass until insulin production collapses.
Beta Cells Under Stress May Make Themselves Targets
For years, the dominant view cast beta cells as passive victims of a misdirected immune system. More recent work suggests they may inadvertently contribute to their own destruction. When beta cells are stressed, particularly through a process called endoplasmic reticulum stress, they can modify their own proteins in unusual ways. These modifications create what researchers call neo-epitopes: altered protein fragments that the immune system hasn’t learned to tolerate. Some of these modified fragments bind more tightly to the HLA molecules that present them to T cells, making them more visible and more provocative to the immune system.4Frontiers in Endocrinology. The Role of β Cell Stress and Neo-Epitopes in the Immunopathology of Type 1 Diabetes
This matters because it means the autoimmune process isn’t purely an immune system malfunction. The beta cells themselves, when under metabolic or inflammatory stress, may change in ways that attract immune attention. It’s a feedback loop: early immune infiltration stresses beta cells, stressed beta cells become more immunogenic, and that draws in more immune cells. Understanding this loop has shifted thinking about intervention targets, since calming beta cell stress might slow the immune attack even without directly suppressing the immune system.
The Genetic Foundation
Type 1 diabetes has one of the strongest genetic associations of any autoimmune disease, and most of that risk traces to a specific region of the genome called HLA, which encodes proteins the immune system uses to distinguish self from non-self. The highest-risk combination involves carrying two particular gene variants, commonly abbreviated DR3 and DR4. People who inherit one copy of each have a dramatically elevated risk compared to the general population.5PubMed Central. Genetics of the HLA region in the prediction of type 1 diabetes The DR3 variant also shows up as a strong risk factor in more recent studies across different populations.6Frontiers in Endocrinology. HLA class II alleles and haplotypes associated with susceptibility to type 1 diabetes and to type 1 diabetes with concomitant autoimmune diseases Other HLA variants actually protect against the disease. One protective variant, known as DR2, is so strongly associated with reduced risk that carrying it makes type 1 diabetes vanishingly unlikely.5PubMed Central. Genetics of the HLA region in the prediction of type 1 diabetes
But HLA genes aren’t the whole story. Dozens of other genes scattered across the genome also nudge risk up or down. Variants in genes like PTPN22 and INS are among the most consistent non-HLA risk factors, and they appear to affect different stages of the disease process. Some influence whether autoimmunity starts at all, while others affect how quickly autoimmunity progresses to full-blown diabetes once it has begun.7Frontiers in Immunology. Non-HLA Gene Polymorphisms in the Pathogenesis of Type 1 Diabetes: Phase and Endotype Specific Effects Recent large-scale genetic studies have identified roughly 70 non-HLA regions linked to type 1 diabetes risk, with over a third of those variants also connected to insulin secretion or insulin resistance pathways.8PubMed. Shared non-HLA genetic architecture across diverse ancestries links insulin secretion and resistance to type 1 diabetes That’s a surprising finding, because insulin resistance is typically thought of as a type 2 diabetes problem. It suggests the metabolic side of type 1 diabetes may be more complex than the simple “immune system kills all the beta cells” narrative implies.
Still, genetics alone doesn’t seal anyone’s fate. The concordance rate among identical twins is only about 30 to 50 percent, meaning that even with an identical genome, half or more of co-twins never develop the disease. Something in the environment has to be involved.
Viruses as a Trigger
Of all the environmental suspects, enteroviruses, particularly a group called coxsackievirus B, have the strongest and most consistent evidence linking them to type 1 diabetes. The case has built slowly over decades through prospective birth cohorts, autopsy studies of pancreases from people with the disease, and growing mechanistic data.9PubMed. Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention Recent studies continue to strengthen the association, suggesting that enteroviruses may trigger autoimmunity through persistent low-grade infections rather than a single acute illness.10PubMed Central. Enteroviruses and Type 1 Diabetes: Multiple Mechanisms and Factors?
The timing matters. In a study of genetically susceptible children, coxsackievirus B infections occurring six months or more before the first detection of islet autoantibodies were associated with roughly double the risk of developing that autoimmunity.11PubMed Central. Coxsackievirus B Infections Are Associated With the Risk of Islet Autoimmunity in Children With Strong Genetic Susceptibility to Type 1 Diabetes The gap between infection and autoantibody appearance suggests the virus doesn’t destroy beta cells directly in a sudden assault. Instead, the infection may set off a chain of immune events: the virus infects beta cells, the immune system clears the virus but in doing so becomes sensitized to beta cell proteins, and months later that sensitization manifests as persistent autoimmunity.
Enteroviruses are extremely common childhood infections, yet most children who catch them never develop diabetes. This is where genetic susceptibility re-enters the picture. The same HLA variants that confer high type 1 diabetes risk also shape how the immune system responds to viral infections. A virus that passes uneventfully through one child’s immune system may set off a harmful autoimmune cascade in another child whose HLA genes present viral and beta cell proteins in overlapping ways.
The Gut Connection
The gut microbiome has emerged as another piece of the puzzle, though the evidence here is less mature than for viruses. Children who go on to develop type 1 diabetes tend to have less diverse gut bacteria and higher intestinal permeability, sometimes called a “leaky gut,” compared to matched controls.12PubMed Central. Gut microbiome in type 1 diabetes: A comprehensive review When the gut barrier is compromised, bacterial products, food proteins, and other substances can cross into the bloodstream and reach pancreatic lymph nodes, potentially provoking or worsening the autoimmune process.
A persistent question is whether the leaky gut comes first or is a consequence of the disease process already underway. Some researchers have argued that the inflammation and blood sugar disruption of early diabetes itself damages the gut lining. But several studies have found that increased intestinal permeability and microbial imbalance appear before either insulitis or clinical disease onset, suggesting the gut changes may be a contributing cause rather than purely a result.13Frontiers in Endocrinology. Evaluating the Causal Role of Gut Microbiota in Type 1 Diabetes and Its Possible Pathogenic Mechanisms If that’s correct, factors that shape the early microbiome, including mode of delivery, antibiotic use in infancy, and early diet, could indirectly influence diabetes risk.
Diet, Sunlight, and Early Life Exposures
Cow’s milk has been investigated for decades as a dietary risk factor for type 1 diabetes, and the evidence is nuanced. A large systematic review found that higher childhood intake of cow’s milk products was associated with increased risk of both islet autoimmunity and type 1 diabetes, though breastfeeding duration and timing of solid food introduction on their own were not clearly linked.14eBioMedicine. Dietary factors and risk of islet autoimmunity and type 1 diabetes: a systematic review and meta-analysis A study from the TRIGR trial, which followed genetically at-risk children, found that higher concentrations of antibodies against cow’s milk proteins, even those present in cord blood at birth, were associated with increased risk of developing both islet autoimmunity and type 1 diabetes.15PubMed Central. High Concentrations of Immunoglobulin G Against Cow Milk Proteins and Frequency of Cow Milk Consumption Are Associated With the Development of Islet Autoimmunity and Type 1 Diabetes
Some smaller studies have also pointed to the combination of early cow’s milk introduction and late introduction of gluten-containing foods as a risk factor for autoantibody development.16British Journal of Nutrition. Dietary risk factors for the emergence of type 1 diabetes-related autoantibodies in 2½-year-old Swedish children The mechanisms remain unclear. Cow’s milk proteins might provoke an immune response that cross-reacts with beta cell antigens, or they might affect the developing gut barrier. The effect sizes are modest, and no public health authority recommends eliminating cow’s milk to prevent type 1 diabetes. But the pattern is consistent enough that researchers take it seriously.
Vitamin D adds another layer. Type 1 diabetes is more common at higher latitudes, where sunlight exposure and vitamin D synthesis are lower. A study of incidence data from 51 regions worldwide found that lower ultraviolet B radiation was significantly associated with higher rates of childhood type 1 diabetes, and that incidence approached zero in regions with the highest UV exposure.17PubMed. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide Vitamin D deficiency has been repeatedly documented in people with type 1 diabetes, and the seasonal variation in diagnosis rates aligns with seasonal changes in vitamin D levels.18PubMed Central. The role of vitamin d deficiency in the incidence, progression, and complications of type 1 diabetes mellitus Vitamin D is known to modulate immune function, so the hypothesis that low levels could permit autoimmunity to take hold is biologically plausible, though definitive proof from randomized prevention trials is still lacking.
Perinatal factors round out the early-life picture. Older maternal age at delivery and higher birth weight have been weakly associated with increased risk, and children delivered by cesarean section show a slightly elevated rate of type 1 diabetes. One proposed explanation for the cesarean link is reduced exposure to maternal vaginal and gut bacteria during birth, which could alter the infant’s early microbiome in ways that affect immune development.19PubMed. The prenatal environment and type 1 diabetes These associations are modest and inconsistent across studies, so they’re unlikely to be primary drivers, but they may contribute in the context of other risk factors.
The Hygiene Hypothesis
Type 1 diabetes rates have been rising sharply in many countries over the past several decades, far too fast to be explained by genetic changes. The hygiene hypothesis proposes that the decline in childhood infections in industrialized societies has left the immune system without its usual calibration targets, making autoimmune misfires more likely.20PubMed Central. The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes The idea is supported by animal data and the broad observation that autoimmune diseases, not just type 1 diabetes, have increased in tandem with improved sanitation and reduced infectious disease burdens.21PubMed Central. The microbiology of human hygiene and its impact on type 1 diabetes
This might seem paradoxical alongside the evidence that specific viruses like coxsackievirus B increase diabetes risk. But the hygiene hypothesis doesn’t claim that all infections are protective. Rather, it suggests that a diverse array of early microbial exposures trains the immune system to tolerate self-tissues, while certain specific infections, particularly those that target the pancreas, can tip the balance toward autoimmunity. The net effect of living in a cleaner environment may be fewer calibrating infections and the same number of dangerous ones, shifting the odds in the wrong direction.
Stages Before Symptoms Appear
Type 1 diabetes doesn’t begin the day someone shows up at an emergency room with high blood sugar. The autoimmune process unfolds over months or years, and researchers have now formalized this into a staging system. Stage 1 is defined by the presence of two or more islet autoantibodies with normal blood sugar. Stage 2 adds abnormal blood sugar regulation, though the person still has no symptoms. Stage 3 is classical symptomatic diabetes.22PubMed Central. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association Children identified at Stage 1 through screening programs can be monitored for metabolic changes that signal progression to Stage 2.23PubMed Central. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening
This staging framework matters for two reasons. First, it shifts the clinical mindset from reactive to proactive: type 1 diabetes is a disease you can detect years before it becomes an emergency. Second, it opens a window for intervention. If autoimmunity can be identified early, treatments that slow progression could buy years of preserved beta cell function, delaying or even preventing full insulin dependence.
Slowing the Disease With Teplizumab
In 2022, the FDA approved teplizumab as the first disease-modifying therapy for type 1 diabetes, marking a milestone after decades of failed attempts to intervene in the autoimmune process.24PubMed. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus Teplizumab is an antibody that targets CD3, a molecule on T cells. In a landmark trial, high-risk relatives of people with type 1 diabetes who received a single 14-day course of teplizumab took a median of about four years to progress to clinical diabetes, compared to about two years for those on placebo. Roughly 57 percent of the teplizumab group remained diabetes-free during follow-up, compared to only 28 percent of the placebo group.25PubMed Central. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Teplizumab doesn’t cure the disease or permanently halt autoimmunity. What it appears to do is recalibrate the immune response enough to delay the point at which beta cell loss becomes clinically significant. Even a delay of two years is meaningful: for a child, that’s two years of less intensive management, reduced risk of diabetic emergencies, and more time with the body’s own insulin production partially intact. For researchers, it’s proof that intervening in the autoimmune process is possible in humans, not just in lab animals.
When Type 1 Diabetes Appears in Adults
Type 1 diabetes is often thought of as a childhood disease, but a substantial fraction of cases are diagnosed in adulthood. A slowly progressing form known as latent autoimmune diabetes in adults, or LADA, shares features with both type 1 and type 2 diabetes. People with LADA have autoantibodies against beta cells, confirming an autoimmune process, but their beta cell decline is more gradual than in classic childhood-onset type 1 diabetes. Research has found marked genetic differences between LADA and childhood type 1 diabetes, including differences in inflammatory gene variants that could explain the slower pace of destruction.26PubMed. Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus
LADA is frequently misdiagnosed as type 2 diabetes because it appears in adults who may not fit the stereotype of a type 1 patient. The distinction matters clinically: people with LADA will eventually need insulin, and starting it earlier may help preserve remaining beta cell function. If you’re diagnosed with “type 2 diabetes” but aren’t overweight, have no family history of type 2, or find that your blood sugar is hard to control with standard type 2 medications, autoantibody testing can clarify whether an autoimmune process is at work.
Environmental Chemicals and Epigenetic Changes
Beyond viruses and diet, a less-studied category of environmental factors involves chemical exposures. A review of the evidence concluded that it is plausible for environmental chemicals to contribute to type 1 diabetes development by impairing beta cell function, disrupting immune regulation, or both. Multiple chemicals could act together in genetically susceptible individuals, possibly through hormonal or epigenetic pathways.27PubMed Central. Can exposure to environmental chemicals increase the risk of diabetes type 1 development? The data here is largely preliminary, drawing on animal studies and mechanistic plausibility rather than large human cohorts. But given how many environmental exposures have changed in the same decades that type 1 diabetes rates have risen, it’s a line of inquiry worth watching.
Epigenetics offers one possible bridge between environmental exposures and disease. Changes in DNA methylation, which can turn genes on or off without altering the underlying DNA sequence, have been detected before the onset of autoimmunity in children who later develop type 1 diabetes. These methylation differences may reflect responses to environmental triggers and could influence immune or beta cell gene activity in ways that promote disease.28Scientific Reports. Longitudinal DNA methylation differences precede type 1 diabetes Whether these epigenetic changes are truly on the causal path or are early markers of a process already set in motion remains an open question. But the fact that they precede clinical autoimmunity, and that they affect genes with plausible roles in immune regulation, makes them a promising area for future risk prediction tools.
Why Translating Discoveries Into Treatments Is So Hard
For nearly 30 years, the primary animal model for type 1 diabetes research has been the NOD mouse, a strain that spontaneously develops autoimmune diabetes. The NOD mouse has been invaluable for understanding the genetic and immune basis of the disease, but it has also led to frustration: hundreds of interventions that prevented or reversed diabetes in NOD mice failed when tested in humans.29PubMed Central. The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future The appearance of immune infiltration in the mouse pancreas differs from what’s seen in many human patients, and the mouse immune system, while similar in broad strokes, diverges in important details.30PubMed. Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease
The success of teplizumab is encouraging precisely because it overcame this translational gap. But the broader lesson is humbling: type 1 diabetes is not a single uniform disease. It likely involves multiple autoimmune pathways, varying rates of beta cell loss, different predominant triggers in different people, and distinct genetic architectures depending on age of onset and ancestry. Treating it as one disease with one cause has led to oversimplified models. The field is moving toward recognizing subtypes and endotypes, which may eventually allow for more targeted prevention and treatment strategies tailored to an individual’s specific combination of genetic risk and environmental exposures.